Targeting myeloid signalling pathways to unleash T cells

Unlike in numerous other tumors, the efficacy of checkpoint inhibitor-based immunotherapies in colorectal cancer (CRC) is restricted to the small subgroup of patients with mismatch repair-deficiency or microsatellite instability accounting for only a small minority of cases.1 The vast majority of pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Michl, Patrick (VerfasserIn) , Krug, Sebastian (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: December 2023
In: Gut
Year: 2023, Jahrgang: 72, Heft: 12, Pages: 2223-2225
ISSN:1468-3288
DOI:10.1136/gutjnl-2023-330706
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1136/gutjnl-2023-330706
Verlag, kostenfrei, Volltext: https://gut.bmj.com/content/72/12/2223
Volltext
Verfasserangaben:Patrick Michl, Sebastian Krug

MARC

LEADER 00000caa a2200000 c 4500
001 1871302137
003 DE-627
005 20250312122026.0
007 cr uuu---uuuuu
008 231127s2023 xx |||||o 00| ||eng c
024 7 |a 10.1136/gutjnl-2023-330706  |2 doi 
035 |a (DE-627)1871302137 
035 |a (DE-599)KXP1871302137 
035 |a (OCoLC)1425209220 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Michl, Patrick  |d 1971-  |e VerfasserIn  |0 (DE-588)121336328  |0 (DE-627)081239203  |0 (DE-576)292654677  |4 aut 
245 1 0 |a Targeting myeloid signalling pathways to unleash T cells  |c Patrick Michl, Sebastian Krug 
264 1 |c December 2023 
300 |b Illustrationen 
300 |a 3 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 27.11.2023 
500 |a Online verfügbar: 20.10.2023 
520 |a Unlike in numerous other tumors, the efficacy of checkpoint inhibitor-based immunotherapies in colorectal cancer (CRC) is restricted to the small subgroup of patients with mismatch repair-deficiency or microsatellite instability accounting for only a small minority of cases.1 The vast majority of patients with advanced, microsatellite-stable CRC, however, is currently resistant to checkpoint inhibitors and thus are not candidates for regimens containing antibodies targeting inhibitory immune checkpoint receptors. Therefore, it is an urgent unmet clinical need to explore new avenues to render microsatellite-stable CRCs immunologically ‘hot’ and thus susceptible to checkpoint inhibitor-based therapies. - - In many cancers including CRC, resistance to immunotherapy is mainly mediated by the tumour immune microenvironment. Particularly, infiltrating immune cells such as tumour-associated macrophages (TAMs) can polarise into a tumour-promoting, anti-inflammatory M2 phenotype that mediates T cell exhaustion thus rendering the tumour immunologically ‘cold’.2 To date, it remains largely unresolved how to effectively reverse T cell exhaustion in these tumours. Given the intense immunosuppressive impact of M2-polarised TAM on T cells, signalling pathways in M2-TAMs represent an interesting avenue to indirectly enhance T cell function.2 - - In this context, in GUT , Li et al 3 identified a promising myeloid signalling target: The membrane spanning four domains A4A (MS4A4A) protein that … 
650 4 |a COLORECTAL CANCER 
650 4 |a IMMUNOTHERAPY 
650 4 |a MACROPHAGES 
700 1 |a Krug, Sebastian  |d 1985-  |e VerfasserIn  |0 (DE-588)1014103975  |0 (DE-627)705168034  |0 (DE-576)348318332  |4 aut 
773 0 8 |i Enthalten in  |t Gut  |d London : BMJ Publishing Group, 1960  |g 72(2023), 12 vom: Dez., Seite 2223-2225  |h Online-Ressource  |w (DE-627)302725628  |w (DE-600)1492637-4  |w (DE-576)082435405  |x 1468-3288  |7 nnas  |a Targeting myeloid signalling pathways to unleash T cells 
773 1 8 |g volume:72  |g year:2023  |g number:12  |g month:12  |g pages:2223-2225  |g extent:3  |a Targeting myeloid signalling pathways to unleash T cells 
856 4 0 |u https://doi.org/10.1136/gutjnl-2023-330706  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://gut.bmj.com/content/72/12/2223  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20231127 
993 |a Article 
994 |a 2023 
998 |g 1014103975  |a Krug, Sebastian  |m 1014103975:Krug, Sebastian  |d 910000  |d 910100  |e 910000PK1014103975  |e 910100PK1014103975  |k 0/910000/  |k 1/910000/910100/  |p 2  |y j 
998 |g 121336328  |a Michl, Patrick  |m 121336328:Michl, Patrick  |d 910000  |d 910100  |e 910000PM121336328  |e 910100PM121336328  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1871302137  |e 4418506780 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"December 2023","dateIssuedKey":"2023"}],"relHost":[{"id":{"zdb":["1492637-4"],"eki":["302725628"],"issn":["1468-3288"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Gut","title":"Gut","subtitle":"an international journal of gastroenterology and hepatology"}],"origin":[{"publisherPlace":"London","dateIssuedKey":"1960","dateIssuedDisp":"1960-","publisher":"BMJ Publishing Group"}],"recId":"302725628","disp":"Targeting myeloid signalling pathways to unleash T cellsGut","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"Gut online"},{"title":"eGut"}],"part":{"year":"2023","volume":"72","issue":"12","extent":"3","pages":"2223-2225","text":"72(2023), 12 vom: Dez., Seite 2223-2225"},"language":["eng"],"pubHistory":["1.1960 -"],"note":["Gesehen am 07.09.12"]}],"id":{"eki":["1871302137"],"doi":["10.1136/gutjnl-2023-330706"]},"physDesc":[{"extent":"3 S.","noteIll":"Illustrationen"}],"title":[{"title_sort":"Targeting myeloid signalling pathways to unleash T cells","title":"Targeting myeloid signalling pathways to unleash T cells"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 27.11.2023","Online verfügbar: 20.10.2023"],"recId":"1871302137","person":[{"given":"Patrick","display":"Michl, Patrick","role":"aut","family":"Michl"},{"display":"Krug, Sebastian","given":"Sebastian","role":"aut","family":"Krug"}],"name":{"displayForm":["Patrick Michl, Sebastian Krug"]},"language":["eng"]} 
SRT |a MICHLPATRITARGETINGM2023